Selecting a sterile pharmaceutical contract manufacturer is a patient-protection decision. A facility may have an apparently matching line, but a defensible choice requires evidence that its people, premises, utilities, process, microbiology, quality system and governance can control the risks of the specific product.
1. Verify legal identity, licensed scope and current status
Begin with the legal entity, manufacturing site address, authorization scope and the dosage forms and activities covered. Confirm the source directly through the responsible authority or authenticated records. A corporate brochure, third-party directory or past certificate is not a substitute for current scope verification.
2. Match the product to the specific manufacturing train
“Sterile injectables” is too broad. Identify whether the project is aseptically processed or terminally sterilized; solution, suspension, sterile powder or lyophilized product; vial, ampoule, syringe or other presentation; and the expected batch size, components and handling conditions. Then map the actual compounding, filtration, filling, lyophilization or sterilization, inspection, packaging and storage route.
3. Assess the contamination control strategy as one system
WHO TRS 1044 Annex 2 and EU/PIC/S Annex 1 frame sterile manufacture around a comprehensive contamination control strategy, pharmaceutical quality system, facilities, barrier technologies, utilities, personnel, monitoring and lifecycle control. [1] [2] [5] Ask how the site identifies microbial, particulate and endotoxin/pyrogen risks and how controls across design, procedures, monitoring and trending work together.
4. Review sterile-process evidence
- Aseptic process simulation: design, interventions, worst-case coverage, frequency, incubation, failures and corrective action.
- Environmental and personnel monitoring: locations, limits, methods, recovery, trend review and response to adverse signals.
- Sterilization/depyrogenation: cycle development, load patterns, biological or physical evidence, requalification and change control.
- Sterile filtration: filter compatibility, bacterial retention, integrity testing, pre-use/post-sterilization strategy where applicable and hold times.
- Container-closure integrity: method suitability, lifecycle coverage, transport and stability linkage.
- Lyophilization: loading, cycle transfer, chamber control, interventions, stopper position, cleaning and product-specific scale effects.
FDA's aseptic-processing guidance also covers buildings, personnel, components, sterilization, media fills, environmental monitoring, laboratory controls and documentation. No single release test can compensate for weak sterile-process control. [3]
5. Examine people and behavior, not only documents
Observe gowning qualification, aseptic technique, intervention discipline, line clearance, material flow and supervisor response to abnormal conditions. Review training effectiveness and disqualification/requalification practices. Sterile quality culture is visible in whether operators stop and escalate when control is uncertain.
6. Audit the laboratory and data trail
Follow one recent batch from raw data to reported result. Sample microbiology, sterility, endotoxin, bioburden, particulate, chemistry and stability workflows as applicable. Confirm original data, metadata, audit trails, invalidation practice, method suitability, OOS/OOT investigations and record retention. A clean summary report is not enough if the supporting trail cannot be reconstructed.
7. Test the quality system with recent examples
Select real deviations, CAPA, changes, complaints, maintenance events and environmental excursions. Ask whether root causes are scientifically supported, impact assessments include all affected batches and markets, CAPA effectiveness is checked, and repeat events are trended. Review management oversight and whether quality decisions remain independent of schedule pressure.
8. Put inspection history in context
Inspection history is useful evidence, but not a permanent certification of a facility or a guarantee for a new product. Confirm the authority, date, scope, classification, observations, responses and current remediation status through official sources where possible. FDA provides public resources for inspection and compliance information. [6]
9. Evaluate transfer and supply execution
Assess project leadership, sending/receiving-site roles, gap analysis, document control, change management, analytical transfer, validation, stability, release, material sourcing, forecast, safety stock, lead time, backup utilities and business continuity. For China-based sterile contract manufacture, the current NMPA announcement also includes dosage-form experience expectations and should be reviewed for the particular arrangement. [4]
10. Use decision gates and red flags
Legal entity, site and relevant manufacturing activities are current and verifiable.
The proposed route, equipment, components, batch scale and controls are technically credible.
Contamination control, APS, monitoring, sterilization/filtration and CCI evidence support the route.
Recent records demonstrate effective investigations, CAPA, change control and data integrity.
Responsibilities, acceptance criteria, capacity, materials, timing and continuity are realistic.
Red flags include reluctance to show source records, unexplained recurring excursions, weak APS design, late or superficial investigations, uncontrolled subcontracting, unexplained data deletion, a proposed route that does not match the product, or commercial dates fixed before feasibility is understood.
Frequently asked questions
Is a successful inspection enough to select a manufacturer?
No. It provides dated, scoped evidence. Product-specific technical, quality, regulatory and supply due diligence remains necessary.
Should an on-site audit always be performed?
The approach should be risk-based, but sterile commercial supply normally warrants direct site-level due diligence before final commitment.
What is the most important sterile-manufacturing document?
No single document is sufficient. The contamination control strategy should connect multiple controls and be supported by operational evidence.
How should terminal sterilization and aseptic processing be compared?
They require different risk models. The appropriate route must be justified by product characteristics, process feasibility and applicable requirements.
Can public information replace confidential due diligence?
No. Public information supports screening and verification; confidential review is needed for product- and site-specific evidence.
Authoritative sources
- WHO TRS 1044, Annex 2 — Good manufacturing practices for sterile pharmaceutical products
- European Commission — EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products
- U.S. FDA — Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice
- NMPA — Announcement on Strengthening Supervision and Administration of Contract Manufacturing of Drugs (No. 134, 2025)
- PIC/S — PE 009-17 Annexes, Annex 1: Manufacture of Sterile Medicinal Products
- U.S. FDA — Pharmaceutical Inspections and Compliance
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.